Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

Globus Medical saw a strong 2024 with multiple new product launches and more innovation is on the way, President and CEO Dan Scavilla said in a Feb. 20 earnings ...

BTIG analyst Ryan Zimmerman raised the firm’s price target on Globus Medical (GMED) to $94 from $91 and keeps a Buy rating on the shares after ...

Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...

Globus Medical Inc (GMED) reports a 61% annual revenue increase and outlines strategic plans following the Nevro acquisition.

Medical technologies specialist Globus Medical (NYSE:GMED) reported impressive results for the fourth quarter of 2024 on ...

Globus Medical saw fourth quarter net sales grow 6.6% year over year, and full year sales leapt 60.6%, according to financial results posted Feb. 20.

Globus Medical expects full-year earnings in the range of $3.40 to $3.50 per share, with revenue in the range of $2.66 billion to $2.69 billion. This story was generated by Automated Insights ( http:/ ...

GMED earnings call for the period ending December 31, 2024.

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...